Bicara Therapeutics Inc. (BCAX) intrinsic value & 10-year financials
Bicara Therapeutics Inc. (BCAX) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $16.78
- Market cap
- $917.5B
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -15.6%
- Free cash flow (FY2025)
- -$107.1M
BCAX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$137.9M | -$2.52 | -$107.1M | — | -101.2% |
| FY2024 | — | -$68.0M | -$4.05 | -$74.8M | — | 43.8% |
| FY2023 | — | -$52.0M | -$3.09 | -$46.2M | — | 10.5% |
| FY2022 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Bicara Therapeutics Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Bicara Therapeutics Inc. has historically struggled to out-earn its cost of capital, averaging just -15.6% ROIC.
Bicara Therapeutics Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Bicara Therapeutics Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.